Tissue-specific effector functions of innate lymphoid cells

Immunology

Volumn 139, Issue 4, 2013, Pages 416-427

  Björkström, Niklas K ^a   Kekäläinen, Eliisa ^a   Mjösberg, Jenny ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Effector functions; Innate lymphoid cells; Natural killer cells; Tissue immunology

Indexed keywords

ALPHA4 INTEGRIN; AMPHIREGULIN; ANGIOGENIC FACTOR; AROMATIC HYDROCARBON RECEPTOR; BETA7 INTEGRIN; CD16 ANTIGEN; EPIDERMAL GROWTH FACTOR; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 25; INTERLEUKIN 33; INTERLEUKIN 8; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PERFORIN; PLACENTAL GROWTH FACTOR; RANTES; STEM CELL FACTOR RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; VASCULOTROPIN;

AIRWAY; BILIARY CIRRHOSIS; BONE MARROW CELL; CELL FUNCTION; CELL POPULATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; CYTOTOXICITY; ENZYME SYNTHESIS; EPITHELIUM CELL; HEPATITIS C; HUMAN; INNATE IMMUNITY; INTESTINE; LIVER; LIVER CELL CARCINOMA; LIVER INJURY; LUNG; LYMPHOID CELL; LYMPHOID TISSUE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFECTION; REVIEW; SCLEROSING CHOLANGITIS; TARGET CELL; TH17 CELL; TISSUE SPECIFICITY; UTERUS;

EFFECTOR FUNCTIONS; INNATE LYMPHOID CELLS; NATURAL KILLER CELLS; TISSUE IMMUNOLOGY;

ANIMALS; CYTOKINES; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; KILLER CELLS, NATURAL; LIVER; LUNG; LYMPHOCYTE SUBSETS; MALE; PHENOTYPE; RECEPTORS, CYTOKINE; SIGNAL TRANSDUCTION; UTERUS;

EID: 84879816912     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12098     Document Type: Review

References (145)

1. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975; 5:112-7.
2. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol 2008; 9:503-10.
3. Spits H, Cupedo T. Innate lymphoid cells: emerging insights in development, lineage relationships, and function. Annu Rev Immunol 2012; 30:647-75.
4. Eberl G, Marmon S, Sunshine MJ, Rennert PD, Choi Y, Littman DR. An essential function for the nuclear receptor RORγ(t) in the generation of fetal lymphoid tissue inducer cells. Nat Immunol 2004; 5:64-73.
5. + cells that provide innate mucosal immune defense. Immunity 2008; 29:958-70.
6. Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov II, Littman DR, O'Shea JJ. Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22. J Exp Med 2009; 206:35-41.
7. + lineage distinct from conventional natural killer cells. J Exp Med 2010; 207:281-90.
8. Hughes T, Becknell B, McClory S et al. Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood 2009; 113:4008-10.
9. + cell populations in gut and skin. Nat Immunol 2009; 10:75-82.
10. + natural killer-like cells. Nat Immunol 2009; 10:66-74.
11. Bernink JH, Peters CP, Munneke M et al. Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013; 14:221-9.
12. Mjosberg JM, Trifari S, Crellin NK et al. Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12:1055-62.
13. Monticelli LA, Sonnenberg GF, Abt MC et al. Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus. Nat Immunol 2011; 12:1045-54.
14. + lymphoid cells. Nature 2010; 463:540-4.
15. Neill DR, Wong SH, Bellosi A et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 2010; 464:1367-70.
16. Price AE, Liang HE, Sullivan BM et al. Systemically dispersed innate IL-13-expressing cells in type 2 immunity. Proc Natl Acad Sci USA 2010; 107:11489-94.
17. Hoyler T, Klose CS, Souabni A et al. The transcription factor GATA-3 controls cell fate and maintenance of type 2 innate lymphoid cells. Immunity 2012; 37:634-48.
18. Mjosberg J, Bernink J, Golebski K et al. The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cells. Immunity 2012; 37:649-59.
19. Spits H, Artis D, Colonna M et al. Innate lymphoid cells - a proposal for uniform nomenclature. Nat Rev Immunol 2013; 13:145-9.
20. Carlsten M, Bjorkstrom NK, Norell H et al. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res 2007; 67:1317-25.
21. Bjorkstrom NK, Lindgren T, Stoltz M et al. Rapid expansion and long-term persistence of elevated NK cell numbers in humans infected with hantavirus. J Exp Med 2011; 208:13-21.
22. Shi FD, Ljunggren HG, La Cava A, Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011; 11:658-71.
23. Phillips JH, Hori T, Nagler A, Bhat N, Spits H, Lanier LL. Ontogeny of human natural killer (NK) cells: fetal NK cells mediate cytolytic function and express cytoplasmic CD3εδ proteins. J Exp Med 1992; 175:1055-66.
24. Boos MD, Yokota Y, Eberl G, Kee BL. Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med 2007; 204:1119-30.
25. Gascoyne DM, Long E, Veiga-Fernandes H et al. The basic leucine zipper transcription factor E4BP4 is essential for natural killer cell development. Nat Immunol 2009; 10:1118-24.
26. Colucci F, Samson SI, DeKoter RP, Lantz O, Singh H, Di Santo JP. Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood 2001; 97:2625-32.
27. Barton K, Muthusamy N, Fischer C et al. The Ets-1 transcription factor is required for the development of natural killer cells in mice. Immunity 1998; 9:555-63.
28. Lacorazza HD, Miyazaki Y, Di Cristofano A et al. The ETS protein MEF plays a critical role in perforin gene expression and the development of natural killer and NK-T cells. Immunity 2002; 17:437-49.
29. Taki S, Nakajima S, Ichikawa E, Saito T, Hida S. IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells. J Immunol 2005; 174:6005-12.
30. Samson SI, Richard O, Tavian M et al. GATA-3 promotes maturation, IFN-γ production, and liver-specific homing of NK cells. Immunity 2003; 19:701-11.
31. Townsend MJ, Weinmann AS, Matsuda JL et al. T-bet regulates the terminal maturation and homeostasis of NK and Vα14i NKT cells. Immunity 2004; 20:477-94.
32. Haller O, Wigzell H. Suppression of natural killer cell activity with radioactive strontium: effector cells are marrow dependent. J Immunol 1977; 118:1503-6.
33. bright natural killer cells. Immunity 2005; 22:295-304.
34. Male V, Hughes T, McClory S, Colucci F, Caligiuri MA, Moffett A. Immature NK cells, capable of producing IL-22, are present in human uterine mucosa. J Immunol 2010; 185:3913-8.
35. + immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 2007; 133:559-73.
36. Moroso V, Famili F, Papazian N, Cupedo T, van der Laan LJ, Kazemier G, Metselaar HJ, Kwekkeboom J. NK cells can generate from precursors in the adult human liver. Eur J Immunol 2011; 41:3340-50.
37. Freud AG, Yokohama A, Becknell B et al. Evidence for discrete stages of human natural killer cell differentiation in vivo. J Exp Med 2006; 203:1033-43.
38. Huntington ND, Legrand N, Alves NL et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206:25-34.
39. Bjorkstrom NK, Riese P, Heuts F et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853-64.
40. + natural killer cells after bone marrow transplantation. Blood 1992; 79:3239-44.
41. bright subset. Blood 2001; 97:3146-51.
42. bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101:3052-7.
43. Burt BM, Plitas G, Zhao Z et al. The lytic potential of human liver NK cells is restricted by their limited expression of inhibitory killer Ig-like receptors. J Immunol 2009; 183:1789-96.
44. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Munz C The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172:1455-62.
45. Moffett A, Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol 2006; 6:584-94.
46. Fauriat C, Long EO, Ljunggren HG, Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood 2010; 115:2167-76.
47. Stegmann KA, Bjorkstrom NK, Veber H et al. Interferon-α-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection. Gastroenterology 2010; 138:1885-97.
48. dim NK cells. Blood 2010; 116:1299-307.
49. Bryceson YT, Chiang SC, Darmanin S et al. Molecular mechanisms of natural killer cell activation. J Innate Immun 2011; 3:216-26.
50. Lanier LL. NK cell recognition. Annu Rev Immunol 2005; 23:225-74.
51. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006; 214:73-91.
52. Vivier E, Nunes JA, Vely F. Natural killer cell signaling pathways. Science 2004; 306:1517-9.
53. Ljunggren HG, Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today 1990; 11:237-44.
54. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005; 86:209-39.
55. Brilot F, Strowig T, Roberts SM, Arrey F, Munz C. NK cell survival mediated through the regulatory synapse with human DCs requires IL-15Rα. J Clin Invest 2007; 117:3316-29.
56. Kim S, Poursine-Laurent J, Truscott SM et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005; 436:709-13.
57. Anfossi N, Andre P, Guia S et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006; 25:331-42.
58. Spits H, Di Santo JP. The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling. Nat Immunol 2011; 12:21-7.
59. Mjosberg J, Bernink J, Peters C, Spits H. Transcriptional control of innate lymphoid cells. Eur J Immunol 2012; 42:1916-23.
60. Mebius RE. Organogenesis of lymphoid tissues. Nat Rev Immunol 2003; 3:292-303.
61. Scandella E, Bolinger B, Lattmann E et al. Restoration of lymphoid organ integrity through the interaction of lymphoid tissue-inducer cells with stroma of the T cell zone. Nat Immunol 2008; 9:667-75.
62. + innate lymphoid cells. Front Immunol 2012; 3:72.
63. Cella M, Fuchs A, Vermi W et al. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity. Nature 2009; 457:722-5.
64. + innate lymphoid cells and conventional NK cells. Blood 2013; 121:2234-43.
65. Zheng Y, Valdez PA, Danilenko DM et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14:282-9.
66. + lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity 2011; 34:122-34.
67. + immature human natural killer cells in secondary lymphoid tissue. Immunity 2010; 32:803-14.
68. + LTi-like innate lymphoid cells by Toll-like receptor 2. Immunity 2010; 33:752-64.
69. Lee JS, Cella M, McDonald KG et al. AHR drives the development of gut ILC22 cells and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat Immunol 2012; 13:144-51.
70. Qiu J, Heller JJ, Guo X et al. The aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells. Immunity 2012; 36:92-104.
71. Kiss EA, Vonarbourg C, Kopfmann S et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science 2011; 334:1561-5.
72. + cell subsets from Id2-dependent precursors. J Exp Med 2010; 207:273-80.
73. Narni-Mancinelli E, Chaix J, Fenis A et al. Fate mapping analysis of lymphoid cells expressing the NKp46 cell surface receptor. Proc Natl Acad Sci USA 2011; 108:18324-9.
74. + innate lymphoid cells. Science 2010; 330:665-9.
75. + innate lymphocytes. Immunity 2010; 33:736-51.
76. Satoh-Takayama N, Dumoutier L, Lesjean-Pottier S, Ribeiro VS, Mandelboim O, Renauld JC, Vosshenrich CA, Di Santo JP. The natural cytotoxicity receptor NKp46 is dispensable for IL-22-mediated innate intestinal immune defense against Citrobacter rodentium. J Immunol 2009; 183:6579-87.
77. Cella M, Otero K, Colonna M. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1β reveals intrinsic functional plasticity. Proc Natl Acad Sci USA 2010; 107:10961-6.
78. + innate lymphoid cells. Nature 2013; 494:261-5.
79. Fort MM, Cheung J, Yen D et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity 2001; 15:985-95.
80. Chang YJ, Kim HY, Albacker LA et al. Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity. Nat Immunol 2011; 12:631-8.
81. Wong SH, Walker JA, Jolin HE et al. Transcription factor RORα is critical for nuocyte development. Nat Immunol 2012; 13:229-36.
82. - lymphoid cells. EMBO J 2011; 30:2934-47.
83. + natural killer cells in the intestinal mucosa of patients with Crohn's disease. Gastroenterology 2010; 139:882-92, 92 e1-3.
84. + NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment. Aliment Pharmacol Ther 2011; 33:115-26.
85. Yadav PK, Chen C, Liu Z. Potential role of NK cells in the pathogenesis of inflammatory bowel disease. J Biomed Biotechnol 2011; 2011:348530.
86. Jones DC, Edgar RS, Ahmad T et al. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes Immun 2006; 7:576-82.
87. Ganal SC, Sanos SL, Kallfass C et al. Priming of natural killer cells by nonmucosal mononuclear phagocytes requires instructive signals from commensal microbiota. Immunity 2012; 37:171-86.
88. Hanash AM, Dudakov JA, Hua G et al. Interleukin-22 protects intestinal stem cells from immune-mediated tissue damage and regulates sensitivity to graft versus host disease. Immunity 2012; 37:339-50.
89. + cells. Nat Immunol 2009; 10:83-91.
90. + dendritic cells in response to bacterial flagellin enhances mucosal innate immune defense. Immunity 2012; 36:276-87.
91. Pickert G, Neufert C, Leppkes M et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009; 206:1465-72.
92. Buonocore S, Ahern PP, Uhlig HH et al. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464:1371-5.
93. + innate lymphoid cells. Immunity 2012; 37:674-84.
94. Hueber W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61:1693-700.
95. Sandborn WJ, Feagan BG, Fedorak RN et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135:1130-41.
96. Owyang AM, Zaph C, Wilson EH et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and limits chronic inflammation in the gastrointestinal tract. J Exp Med 2006; 203:843-9.
97. Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology 2006; 43:S54-62.
98. Lunemann S, Schlaphoff V, Cornberg M, Wedemeyer H. NK cells in hepatitis C: role in disease susceptibility and therapy. Dig Dis 2012; 30(Suppl. 1):48-54.
99. Cheent K, Khakoo SI. Natural killer cells and hepatitis C: action and reaction. Gut 2011; 60:268-78.
100. Gao B, Radaeva S, Park O. Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases. J Leukoc Biol 2009; 86:513-28.
101. Hirschfield GM, Liu X, Xu C et al. Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants. N Engl J Med 2009; 360:2544-55.
102. Kumar V, Kato N, Urabe Y et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43:455-8.
103. Khakoo SI, Thio CL, Martin MP et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 2004; 305:872-4.
104. Melum E, Franke A, Schramm C et al. Genome-wide association analysis in primary sclerosing cholangitis identifies two non-HLA susceptibility loci. Nat Genet 2011; 43:17-9.
105. Gregoire C, Chasson L, Luci C et al. The trafficking of natural killer cells. Immunol Rev 2007; 220:169-82.
106. Paust S, Gill HS, Wang BZ et al. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. Nat Immunol 2010; 11:1127-35.
107. Heydtmann M, Lalor PF, Eksteen JA, Hubscher SG, Briskin M, Adams DH. CXC chemokine ligand 16 promotes integrin-mediated adhesion of liver-infiltrating lymphocytes to cholangiocytes and hepatocytes within the inflamed human liver. J Immunol 2005; 174:1055-62.
108. Tu Z, Bozorgzadeh A, Pierce RH, Kurtis J, Crispe IN, Orloff MS. TLR-dependent cross talk between human Kupffer cells and NK cells. J Exp Med 2008; 205:233-44.
109. Kahraman A, Barreyro FJ, Bronk SF et al. TRAIL mediates liver injury by the innate immune system in the bile duct-ligated mouse. Hepatology 2008; 47:1317-30.
110. Ochi M, Ohdan H, Mitsuta H et al. Liver NK cells expressing TRAIL are toxic against self hepatocytes in mice. Hepatology 2004; 39:1321-31.
111. Das A, Hoare M, Davies N et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection. J Exp Med 2008; 205:2111-24.
112. Stegmann KA, Bjorkstrom NK, Ciesek S et al. Interferon α-stimulated natural killer cells from patients with acute hepatitis C virus (HCV) infection recognize HCV-infected and uninfected hepatoma cells via DNAX accessory molecule-1. J Infect Dis 2012; 205:1351-62.
113. Cherrier M, Sawa S, Eberl G. Notch, Id2, and RORgammat sequentially orchestrate the fetal development of lymphoid tissue inducer cells. J Exp Med 2012; 209:729-40.
114. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Karow M, Flavell RA. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity 2007; 27:647-59.
115. Robinson BW, Pinkston P, Crystal RG. Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest 1984; 74:942-50.
116. Ge N, Nishioka Y, Nakamura Y et al. Synthesis and secretion of interleukin-15 by freshly isolated human bronchial epithelial cells. Int Arch Allergy Immunol 2004; 135:235-42.
117. Wang J, Li F, Zheng M, Sun R, Wei H, Tian Z. Lung natural killer cells in mice: phenotype and response to respiratory infection. Immunology 2012; 137:37-47.
118. Platonova S, Cherfils-Vicini J, Damotte D et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res 2011; 71:5412-22.
119. Bordignon C, Villa F, Vecchi A et al. Natural cytotoxic activity in human lungs. Clin Exp Immunol 1982; 47:437-44.
120. Michel T, Poli A, Domingues O et al. Mouse lung and spleen natural killer cells have phenotypic and functional differences, in part influenced by macrophages. PLoS ONE 2012; 7:e51230.
121. Bordignon C, Villa F, Allavena P et al. Inhibition of natural killer activity by human bronchoalveolar macrophages. J Immunol 1982; 129:587-91.
122. Junqueira-Kipnis AP, Kipnis A, Henao Tamayo M et al. Interleukin-10 production by lung macrophages in CBA xid mutant mice infected with Mycobacterium tuberculosis. Immunology 2005; 115:246-52.
123. Lauzon W, Lemaire I. Alveolar macrophage inhibition of lung-associated NK activity: involvement of prostaglandins and transforming growth factor-β1. Exp Lung Res 1994; 20:331-49.
124. Culley FJ. Natural killer cells in infection and inflammation of the lung. Immunology 2009; 128:151-63.
125. Welliver TP, Reed JL, Welliver RC Sr. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J 2008; 27:S92-6.
126. Denney L, Aitken C, Li CK et al. Reduction of natural killer but not effector CD8 T lymphocytes in three consecutive cases of severe/lethal H1N1/09 influenza A virus infection. PLoS ONE 2010; 5:e10675.
127. Kos FJ, Engleman EG. Role of natural killer cells in the generation of influenza virus-specific cytotoxic T cells. Cell Immunol 1996; 173:1-6.
128. Li F, Zhu H, Sun R, Wei H, Tian Z. Natural killer cells are involved in acute lung immune injury caused by respiratory syncytial virus infection. J Virol 2012; 86:2251-8.
129. Stein-Streilein J, Guffee J. In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary influenza infection. J Immunol 1986; 136:1435-41.
130. Abdul-Careem MF, Mian MF, Yue G et al. Critical role of natural killer cells in lung immunopathology during influenza infection in mice. J Infect Dis 2012; 206:167-77.
131. Guo H, Topham DJ. Interleukin-22 (IL-22) production by pulmonary Natural Killer cells and the potential role of IL-22 during primary influenza virus infection. J Virol 2010; 84:7750-9.
132. Kumar P, Thakar MS, Ouyang W, Malarkannan S. IL-22 from conventional NK cells is epithelial regenerative and inflammation protective during influenza infection. Mucosal Immunol 2013; 6:69-82.
133. Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J Immunol 2010; 185:4681-90.
134. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2012; 481:394-8.
135. Barlow JL, Bellosi A, Hardman CS, Drynan LF, Wong SH, Cruickshank JP, McKenzie AN. Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity. J Allergy Clin Immunol 2012; 129:191-8 e1-4.
136. hi lymphoid cells mediate innate type 2 immunity and allergic inflammation in the lungs. J Immunol 2012; 188:1503-13.
137. Halim TY, Krauss RH, Sun AC, Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012; 36:451-63.
138. Kim HY, Chang YJ, Subramanian S et al. Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity. J Allergy Clin Immunol 2012; 129:216-27 e1-6.
139. Klein Wolterink RG, Kleinjan A, van Nimwegen M, Bergen I, de Bruijn M, Levani Y, Hendriks RW. Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma. Eur J Immunol 2012; 42:1106-16.
140. Taube C, Tertilt C, Gyulveszi G et al. IL-22 is produced by innate lymphoid cells and limits inflammation in allergic airway disease. PLoS ONE 2011; 6:e21799.
141. Male V, Sharkey A, Masters L, Kennedy PR, Farrell LE, Moffett A. The effect of pregnancy on the uterine NK cell KIR repertoire. Eur J Immunol 2011; 41:3017-27.
142. Ashkar AA, Di Santo JP, Croy BA. Interferon γ contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 2000; 192:259-70.
143. Hanna J, Goldman-Wohl D, Hamani Y et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12:1065-74.
144. Hiby SE, Walker JJ, O'Shaughnessy KM, Redman CW, Carrington M, Trowsdale J, Moffett A. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J Exp Med 2004; 200:957-65.
145. Hiby SE, Apps R, Sharkey AM et al. Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2. J Clin Invest 2010; 120:4102-10.